Description
Calroma 2.5mg Tablets in Pakistan — Letrozole | Caliph Pharma
Calroma 2.5mg in Pakistan is an essential pharmaceutical product by Caliph Pharma containing the active ingredient Letrozole. It is classified as an Aromatase Inhibitor and is primarily indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women. With consistent formulation standards and local availability across Pakistan, Calroma provides patients and healthcare providers with a reliable treatment option.
Product Details
Brand Name: Calroma 2.5mg
Generic Name: Letrozole 2.5mg
Therapeutic Class: Aromatase Inhibitors / Anti-neoplastic agent
Dosage Form: Tablet
Strength: 2.5mg
Package Size: 1×10’s, 3×10’s
Storage Condition: Store below 30 °C, protect from light/moisture
Manufacturer: Caliph Pharmaceuticals (Pvt.) Ltd.
FAQ
What is Calroma 2.5mg used for?
Calroma (Letrozole) is used in postmenopausal women for the adjuvant treatment of hormone receptor-positive early breast cancer, and for first-line treatment of advanced or metastatic breast cancer.
How does Letrozole work?
Letrozole is a non-steroidal Aromatase Inhibitor. It works by blocking the enzyme aromatase, which reduces the amount of estrogen produced in the body, thereby slowing the growth of breast tumors that are sensitive to estrogen.
Is Calroma 2.5mg safe for premenopausal women?
Calroma (Letrozole) is typically indicated for use in women who are postmenopausal. Its use in premenopausal women should be strictly monitored and guided by an oncologist or specialist.
What are the common side effects of Calroma?
Common side effects may include hot flashes, joint pain, muscle pain, fatigue, and headache. Consult your doctor if any side effects persist or worsen.
How to take Calroma 2.5mg?
Take Calroma exactly as prescribed by your doctor, usually once daily. Do not stop taking the medicine without consulting your healthcare provider.
Additional information
| Generic Composition | Letrozole 2.5mg |
|---|---|
| Pack Size | 1×10's, 3×10's |
There are no reviews yet.